Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus plus prednisone versus prednisone for initial treatment of newly diagnosed moderate-to-severe chronic graft-versus-host disease
ChiCTR2200058886Phase 4Recruiting
- Sponsor
- Medical Center of Hematology, Xinqiao Hospital, Army Medical University
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sirolimus and prednisone in chronic graft-versus-host disease (cGVHD) and graft-versus-host disease (GVHD) (2 arms), sponsored by Medical Center of Hematology, Xinqiao Hospital, Army Medical University. Primary endpoint: Overall response rate after 6 months of treatment. Started Apr 2022; status: recruiting.
02
Drugs
sirolimusprednisone
03
Conditions
chronic graft-versus-host disease (cGVHD)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2200058886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058886.